Recce Pharmaceuticals Limited announced the Canadian Patent Office has formally granted a new Patent Family 4 for Recce's anti-infectives "Process for Preparation of Biologically Active Copolymer" in Canada, expiry 2041. The granted Canadian Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably: Process for preparation of RECCE® anti-infectives. Use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more.

Specifically, further validating RECCE® anti- Infectives from studies in Burn Wounds, Urinary Tract Infections, Gonorrhoea, Influenza, SARS-CoV- 2 and more. Administration by oral, inhalation, transdermal delivery or by injection (into the bloodstream, intramuscular and/or intravenous). Administration may also be applied as an aerosol, gel, topical foam or ointment (or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery) This is the first of Recce's wholly owned patents granted in Canada, with further Patent Cooperation Treaty Country (PCT) submissions in respective stages of review.

In July 2023, the Company received AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program. The program is administered by the Canada Revenue Agency and is aimed at incentivising businesses to conduct R&D in Canada, encouraging innovation and technological advancements. Bacterial Pathogens Covered in Family.

Specific examples of such bacterial infections may be selected from the group of bacteria consisting of Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus spp. Viriral Pathogens Covered in Family. Examples of viral infections that may be caused by a range of viruses such as coated viruses (e.g., lipid coated viruses) including herpes, HIV, cytomegalovirus and influenza.

Preferably, the viral infection treated and/or controlled by the method of the invention may be HSV-1, HSV-2, Varicella Zoster Virus (in the form of chicken pox or shingles), HCMV, EBV, Herpes 6, Herpes 7, Herpes 8 and SARS-CoV-2. Other examples include Influenza A, Ross River virus, Coronaviruses responsible for severe acute respiratory syndrome and, SARS-CoV - also generally referred to as COVID-19.